SIRPA and anemia: Both routes of administration led to intratumoral infiltration of Sirpα−/− BMDMs (Supplementary Fig. 2a), while neither method to infuse Sirpα−/− BMDMs caused adverse reactions such as anemia (Supplementary Fig. 2b).